Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)
Zanubrutinib、lenalidomide 和 rituximab 联合环磷酰胺、多柔比星、长春新碱和泼尼松作为非生发中心 B 细胞弥漫性大 B 细胞淋巴瘤的初始治疗：江苏省淋巴瘤协作组 (JCLG) 开展的一项多中心 II 期研究
期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04418-y
Xia, Yi; Miao, Yi; Qian, Siqi; Zhang, Run; Qin, Shuchao; Xie, Xiaoyan; Li, Bingzong; Sha, Yeqin; Tang, Hanning; Jin, Hui; Cao, Lei; Xu, Wei; Fan, Lei; Li, Jianyong; Shi, Wenyu; Zhu, Huayuan
